AstraZeneca Results Presentation Deck
Expanding beyond heart failure in amyloidosis
Cohesive commercial and development strategy across Cardiovascular and Rare Disease
Leveraging strengths and expertise
across Cardiovascular, Rare Disease
OF OF
Farxiga in Heart Failure (HFrEF, HFPEF)
OF F
Ex. ATTR-CM ~400-500k patients WW¹,2
●
Amyloidosis commonly misdiagnosed as HFpEF
TTR and AL represent majority of amyloidosis diagnoses
ATTR amyloidosis
AL amyloidosis
~20k patients US, EU5³
Complementary MOAs needed in ATTR
to address full spectrum of patient need
ATTR-CM
NYHA Patient Severity¹ NYHA I
less severe
STABILISER
SILENCER
DEPLETER
NYHA II
ALXN2060 acoramidis (BridgeBio)
eplontersen (lonis)
NYHA III
29 1. Mohamed-Salem L et al. Int J Cardiol. 2018 Nov 1; 270:192-196. doi: 10.1016/j.ijcard. 2018.06.006 2. Cucaden C, et al. J Nucl Cardiol. 2020 May 8 3. Quock, T. P., et al. Blood Adv. 2018; 2(10):1046-1053; Internal epidemiological
analysis: Mayo Stage Illa + b 4. New York Heart Association (NYHA) Functional Classification. MoA = mechanism of acton.
NYHA IV
more severe
NI006 (Neurimmune)
Building a strategic presence in amyloidosisView entire presentation